Chris Tovey

Chris Tovey has an extensive work experience starting from 1986 when they began their career with GlaxoSmithKline in commercial roles. Chris then moved on to Nabi Biopharmaceuticals as the Vice President and General Manager for the UK & Ireland. Tovey later joined UCB Pharma, where they held various positions including Vice President & Head of Global Marketing Operations, General Manager in Greece, and Global General Manager for Xyrem. In 2018, Tovey became a Non-Executive Director at CanImGuide Therapeutics AB. Chris then joined GW Pharmaceuticals plc as the Chief Operating Officer and also served as a Board Member. Tovey's most recent position was at Jazz Pharmaceuticals, where they served as the Chief Operating Officer. Chris is set to become the Incoming CEO at Destiny Pharma plc in 2023.

Chris Tovey attended the University of Liverpool from 1983 to 1986. Unfortunately, no information is available regarding the degree or field of study pursued during this time.